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Table 1: Investigations undertaken and their performance  
 Abnormal N (%) Median (range) Interpretation of test 
Urinary Free Cortisol 
(nmol/24h)  
17/18 (94) 
 
1126 (41-30287) Abnormal: >275nmol/24h 
 
Midnight

 cortisol  (nmol/l)  27/27 (100) 555 (169-2987) Abnormal: >138nmol/l 
8am cortisol (nmol/L)  10/27 (37) 601 (95-2990) Abnormal: >550nmol/l 
8am ACTH (ng/l): 
         - Pituitary tumours 
         - Adrenal tumours 
         - Ectopic ACTH  
 
 
11/12 (92) 
8/10 (80) 
1/2 (50) 
 
46 (2.5-66) 
4 (2.5-71) 
46 (40-52) 
 
>15ng/l: ACTH-dependent 
<5ng/l: ACTH-independent 
3-15ng/l: ACTH-dependent or 
independent 
LDDST +48h: cortisol (nmol/l) 
(20mcg/kg/day 6hrly)  
20/20 (100) 
 
588 (74-1355) Suppression means cortisol at +48h 
<50nmol/l 
HDDST +48h:  
(80mcg/kg/day 6hrly) 
        - Pituitary tumours 
        - Adrenal tumours 
        - Ectopic ACTH  
Failure of suppression: 
 
1/10 (10) 
6/6 (100) 
1/2 (50) 
 Suppression means cortisol at +48h 
<50% of basal value 
 
CRH test (100mcg)       
        - Pituitary tumours       
        - Adrenal tumours 
        - Ectopic tumour  
Rise in ACTH or Cortisol 
8/9 (89) 
0/1 (0) 
1/2 (50) 
  
Response if: cortisol  >20%  
ACTH  >50% 
 
IPSS with CRH: 
        - Pituitary tumours       
        - Adrenal tumours 
        - Ectopic tumour 
 
5/5 (100) 
-- 
1/1  (100) 
 •Lateralisation: interpetrosal ratio 
of ACTH after CRH >1.4 
•Central-to-peripheral ACTH 
gradient > 2 before, and > 3 after 
CRH administration indicative of 
Cushing disease 
In the second column, the numerator indicates the number of abnormal test result; the denominator indicates the number of 
subjects in whom the test result was available. 
N: Number of patients. %: Percentage. ACTH: Adrenocorticotropic hormone. LDDST: Low dose dexamethasone 
suppression test. HDDST: High dose dexamethasone suppression test. CRH: Corticotropin releasing hormone. IPSS: 
Bilateral inferior petrosal sinus sampling 
 
Sleeping value 
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Table 2: Clinical Presentation and type of treatment administered 
 ALL Cushing 
syndrome patients 
 [N:30] 
Pituitary 
Cushing Disease 
[N:16] 
Adrenal 
Cushing 
[N:11] 
Ectopic 
Cushing  
[N:2] 
Unknown 
etiology  
[N:1] 
CLINICAL PRESENTATION 
Y
ea
rs
 [
M
ed
ia
n
 (
ra
n
g
e)
]  
Age at presentation 
 
8.9 (0.2-15.5) 10 (7-15.5) 1.5 (0.2-10.2) 6.7 (2.0-11.4) 7.0 
Time lapse between 
1st signs and 
diagnosis  
1.0 (0.04 – 6.0) 
 
1.5 (0.1 – 6.0) 
 
0.5 (0.1-3.2) 0.7 (0.04-1.5) 1.0 
N
u
m
b
er
 o
f 
ca
se
s 
(%
) 
Weight gain 23 (76.6%) 15 (94%) 5 (45.4%) 2 (100%) 1 (100%) 
Hirsutism 17 (56.6%) 6 (37.6%) 8 (72.7%) 2 (100%) 1 (100%) 
Acne 15 (50%) 8 (50%) 5 (45.4%) 2 (100%) 0 (0%) 
Hypertension 15 (50%) 8 (50%) 4 (36.4%) 2 (100%) 1 (100%) 
Mental 
changes/poor 
school performance  
13 (43.33%) 7 (43.7%) 4 (36.4%) 2 (100%) 0 (0%) 
Fatigue or 
weakness 
12 (40%) 6 (37.5%) 
4 (36.4%) 2 (100%) 0 (0%) 
Growth retardation 11 (36.6%) 10 (62.5%) 1 (0.9%) 0 (0%) 0 (0%) 
Striae 8 (26.6%) 7 (43.7%) 0 (0%) 0 (0%) 1 (100%) 
Secondary sexual 
development 
Early: 8 (26.6%) 
Delayed: 3 (10%) 
Normal: 19 
(63.3%) 
Early: 5 (31.2%) 
Delayed:3(18.7%) 
Normal: 8 (50%) 
Early:2(18.2%) 
Delayed:0(0%) 
Normal: 
9(82%) 
Early:1(50%) 
Delayed: 0 
Normal: 
1(50%) 
Early:0(0%) 
Delayed:0(0%) 
Normal: 
1(100%) 
Easy bruising 6 (20%) 3 (18.7%) 2 (18.2%) 1 (50%) 0 (0%) 
Sleep disturbances 6 (20%) 3 (18.7%) 2 (18.2%) 0 (0%) 1 (100%) 
Hypokalemia 4 (13.3%) 1 (6.2%) 3 (27.3%) 0 (0%) 0 (0%) 
Hyperpigmentation 2 (6.6%) 2 (12.5%) 
0 (0%) 0 (0%) 0 (0%) 
TYPE OF TREATMENT 
N
u
m
b
er
 o
f 
ca
se
s 
Surgery only 14 9 5 0 0 
Surgery + 
Antihypertensive 
agent/s 
3 1 2 0 * 
Surgery + 
Radiotherapy 
3 3 (+ metyrapone 
in 1 case); (+ 
bilateral 
adrenalectomy in 
1 case)  
0 0 0 
Surgery + 
Metyrapone 
3 1 1 1 0 
Surgery + 
Antihypertensive 
agent/s + 
Metyrapone 
4 2 2 0 0 
Surgery + 
Chemotherapy 
2 0 1 1 (+ phase I 
HIPEC

 trial) 
0 
N: Number of patients. 1st: First *Managed with antihypertensive agents whilst investigations and surgery deferred. Lost to 
follow up in our centre. 
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HIPEC: Hyperthermic Intra-Peritoneal Chemotherapy  
Table 3. Auxology on follow-up of the whole cohort 
 
 Diagnosis 
(n=30) 
6 Months  
(n=17) 
1 Year  
(n=14) 
2 Years  
(n=12) 
End of growth 
(n=4) 
Median height  
(SDS (range)) 
-0.3 (-3.2 to 3.0) -0.5 (-5.0 to 0.4) -0.1 (-3.5 to 1.1) 0.0 (-3.4 to 1.3) -0.5 (-3.1 to 0.4) 
Median weight  
(SDS (range)) 
+1.7 (-2.8 to 4.0) 0.9 (-3.7 to 3.0) 0.6 (-4.0 to 3.8) 1.1 (-2.4 to 4.5) 1.0 (0 to 2.1) 
Median BMI  
(SDS (range)) 
2.1 (-6.5 to 4.6) 1.4 (-1.0 to 3.5) 0.5 (-2.5 to 3.7) 1.1 (-1.0 to +3.9) 1.3 (0 to +2.9) 
Number of cases 
(%) with BMI > 2 
SDS 
14 (46%) 6 (35%) 4 (28%) 3 (25%) 1 (25%) 
Median growth 
velocity (SDS 
(range)) 
  0.6 (-3.7 to 3.8)   
Number of cases 
(%) with 
hypertension 
15 (50%)  4 (28%)    
n: Number of patients. SDS: Standard Deviation Score. 
 
.  
Table 4. Post-treatment endocrine and non-endocrine complications  
  Cushing Disease 
[N:16] 
Adrenal 
hypercortisolism 
[N:11] 
Ectopic 
hypercortisolism 
[N:2] 
HORMONAL COMPLICATIONS 
ACTH deficiency (long term) 6 - - 
Transient Diabetes Insipidus  11 - - 
Persistent Diabetes Insipidus 2 - - 
Childhood GH deficiency 7 - - 
TSH deficiency 3 - - 
Gonadotropin deficiency 2* - - 
Panhypopituitarism (≥4 deficiencies) 1 - - 
Insulin insensitivity 1 - - 
Primary mineralocorticoid deficiency - 3 - 
Primary glucocorticoid deficiency 
(long term) 
- 7 - 
Cortisol suppression (long term) - - 1 
ENDOCRINE UNRELATED COMPLICATIONS 
Relapse 3 1 1 
Incomplete resection 3 - 1 
Second neoplasia - 1 - 
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Death - 1 - 
Deep vein thrombosis 1 - - 
Septic shock - 1 - 
Cerebrospinal fluid leak 1 - - 
Chylous effusion - - 1 
CS: Cushing syndrome. CD: Cushing disease. ACTH: Adrenocorticotropic hormone. GH: Growth hormone. TSH: Thyroid 
stimulating hormone 
*Out of all the 16 cases of CD; all of them old enough to have gone through puberty.  
 
